Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome.

Wooten N, Bakalov VK, Hill S, Bondy CA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2109-14. doi: 10.1210/jc.2007-2266. Epub 2008 Mar 18.

2.

Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.

Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO, Christiansen JS.

Pediatrics. 2002 Nov;110(5):889-96.

PMID:
12415026
4.

The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome.

Ari M, Bakalov VK, Hill S, Bondy CA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4302-5. Epub 2006 Aug 29.

PMID:
16940444
5.
6.

Effect of growth hormone and 17beta-oestradiol treatment on metabolism and body composition in girls with Turner syndrome.

Gravholt CH, Hjerrild BE, Naeraa RW, Engbaek F, Mosekilde L, Christiansen JS.

Clin Endocrinol (Oxf). 2005 May;62(5):616-22.

PMID:
15853835
7.

An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome.

O'Gorman CS, Syme C, Lang J, Bradley TJ, Wells GD, Hamilton JK.

Clin Endocrinol (Oxf). 2013 Jun;78(6):907-13. doi: 10.1111/cen.12079. Epub 2013 Apr 6.

PMID:
23106295
8.

Turner syndrome, insulin sensitivity and growth hormone treatment.

Mazzanti L, Bergamaschi R, Castiglioni L, Zappulla F, Pirazzoli P, Cicognani A.

Horm Res. 2005;64 Suppl 3:51-7. Epub 2006 Jan 20.

PMID:
16439845
9.

Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.

Bredella MA, Lin E, Brick DJ, Gerweck AV, Harrington LM, Torriani M, Thomas BJ, Schoenfeld DA, Breggia A, Rosen CJ, Hemphill LC, Wu Z, Rifai N, Utz AL, Miller KK.

Eur J Endocrinol. 2012 Apr;166(4):601-11. doi: 10.1530/EJE-11-1068. Epub 2012 Jan 24.

10.

Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.

Bredella MA, Gerweck AV, Lin E, Landa MG, Torriani M, Schoenfeld DA, Hemphill LC, Miller KK.

J Clin Endocrinol Metab. 2013 Sep;98(9):3864-72. doi: 10.1210/jc.2013-2063. Epub 2013 Jul 3.

11.

Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S.

JAMA. 2008 Aug 6;300(5):509-19. doi: 10.1001/jama.300.5.509.

12.

Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls.

Misra M, Bredella MA, Tsai P, Mendes N, Miller KK, Klibanski A.

Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E385-92. doi: 10.1152/ajpendo.00052.2008. Epub 2008 Jun 10.

13.

The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.

Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M.

J Clin Endocrinol Metab. 2001 Aug;86(8):3480-7.

PMID:
11502767
14.

Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome.

Van Pareren YK, De Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Drop SL.

J Clin Endocrinol Metab. 2002 Dec;87(12):5442-8.

PMID:
12466334
15.

Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome.

Menke LA, Sas TC, Stijnen T, Zandwijken GR, de Muinck Keizer-Schrama SM, Otten BJ, Wit JM.

Horm Res Paediatr. 2011 Feb;75(2):115-22. doi: 10.1159/000319313. Epub 2010 Sep 3.

PMID:
20814189
16.

Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.

Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL.

J Clin Endocrinol Metab. 1999 Dec;84(12):4607-12.

PMID:
10599727
17.

Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome.

Zeger MP, Shah K, Kowal K, Cutler GB Jr, Kushner H, Ross JL.

Horm Res Paediatr. 2011;75(1):38-46. doi: 10.1159/000317529. Epub 2010 Aug 20.

PMID:
20733274
18.

Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.

Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, Jansen M, Delemarre-van de Waal HA, Stokvis-Brantsma WH, Waelkens JJ, Westerlaken C, Reeser HM, van Trotsenburg AS, Gevers EF, van Buuren S, Dejonckere PH, Hokken-Koelega AC, Otten BJ, Wit JM.

J Clin Endocrinol Metab. 2010 Mar;95(3):1151-60. doi: 10.1210/jc.2009-1821. Epub 2010 Jan 8.

PMID:
20061421
19.

Insulin sensitivity in Turner's syndrome: influence of GH treatment.

Radetti G, Pasquino B, Gottardi E, Boscolo Contadin I, Aimaretti G, Rigon F.

Eur J Endocrinol. 2004 Sep;151(3):351-4.

20.

Insulin resistance in adolescents with Turner syndrome is comparable to obese peers, but the overall metabolic risk is lower due to unknown mechanism.

Wojcik M, Janus D, Zygmunt-Gorska A, Starzyk JB.

J Endocrinol Invest. 2015 Mar;38(3):345-9. doi: 10.1007/s40618-014-0180-8. Epub 2014 Oct 11.

PMID:
25304095

Supplemental Content

Support Center